Literature DB >> 16216833

Variation in survival after diagnosis of breast cancer in Switzerland.

T Fisch1, P Pury, N Probst, A Bordoni, C Bouchardy, H Frick, G Jundt, D De Weck, E Perret, J-M Lutz.   

Abstract

BACKGROUND: Survival after diagnosis of cancer is a key criterion for cancer control. Major survival differences between time periods and countries have been reported by the EUROCARE studies. We investigated whether similar differences by period and region existed in Switzerland.
METHODS: Survival of 11,376 cases of primary invasive female breast cancer diagnosed between 1988 and 1997 and registered in seven Swiss cancer registries covering a population of 3.5 million was analysed.
RESULTS: Comparing the two periods 1988-1992 and 1993-1997, age-standardized 5 year relative survival improved globally from 77% to 81%. Furthermore, multivariate analysis adjusting for age, tumour size and nodal involvement identified regional survival differences. Survival was lowest in the rural parts of German-speaking eastern Switzerland and highest in urbanised regions of the Latin- and German-speaking northwestern parts of the country.
CONCLUSIONS: This study confirms that survival differences are present even in a small and affluent, but culturally diverse, country like Switzerland, raising the issue of heterogeneity in access to care and quality of treatment.

Entities:  

Mesh:

Year:  2005        PMID: 16216833     DOI: 10.1093/annonc/mdi404

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  8 in total

1.  The effects of organized screening programs on the demand for mammography in Switzerland.

Authors:  Mark Pletscher
Journal:  Eur J Health Econ       Date:  2016-11-08

2.  Causes of death and relative survival of older women after a breast cancer diagnosis.

Authors:  Mara A Schonberg; Edward R Marcantonio; Long Ngo; Donglin Li; Rebecca A Silliman; Ellen P McCarthy
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

3.  Prevalence of breast cancer in a defined population of iran.

Authors:  A Rezaianzadeh; S T Heydari; H Hosseini; A A Haghdoost; E Barooti; K B Lankarani
Journal:  Iran Red Crescent Med J       Date:  2011-09-15       Impact factor: 0.611

4.  Cytotoxic and Anticancer Effects of ICD-85 (Venom Derived Peptides) in Human Breast Adenocarcinoma and Normal Human Dermal Fibroblasts.

Authors:  Peyman Kheirandish Zarandi; Abbas Zare Mirakabadi; Fattah Sotoodehnejadnematalahi
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

5.  Landmark Prediction of Survival for Breast Cancer Patients: A Case Study in Tehran, Iran.

Authors:  Behnaz Alafchi; Leili Tapak; Omid Hamidi; Jalal Poorolajal; Hossein Mahjub
Journal:  Iran J Public Health       Date:  2019-12       Impact factor: 1.429

6.  Management and Outcome of Young Women (≤40 Years) with Breast Cancer in Switzerland.

Authors:  Giacomo Montagna; Robin Schaffar; Andrea Bordoni; Alessandra Spitale; Daniela A Terribile; Lorenzo Rossi; Yvan Bergeron; Bernadette W A van der Linden; Isabelle Konzelmann; Sabine Rohrmann; Katharina Staehelin; Manuela Maspoli-Conconi; Jean-Luc Bulliard; Francesco Meani; Olivia Pagani; Elisabetta Rapiti
Journal:  Cancers (Basel)       Date:  2022-03-04       Impact factor: 6.639

7.  Geographic disparities in colorectal cancer survival.

Authors:  Kevin A Henry; Xiaoling Niu; Francis P Boscoe
Journal:  Int J Health Geogr       Date:  2009-07-23       Impact factor: 3.918

8.  Survival analysis of 1148 women diagnosed with breast cancer in Southern Iran.

Authors:  Abbas Rezaianzadeh; Janet Peacock; Daniel Reidpath; Abdolrasoul Talei; Seyed Vahid Hosseini; Davood Mehrabani
Journal:  BMC Cancer       Date:  2009-06-05       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.